• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国腹膜转移瘤的临床流行病学:基于患病率构建专业腹膜转移瘤治疗中心

Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate.

作者信息

Yang Rui, Su Yan-Dong, Ma Ru, Li Yan

机构信息

Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.

Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.

出版信息

Eur J Surg Oncol. 2023 Jan;49(1):173-178. doi: 10.1016/j.ejso.2022.08.023. Epub 2022 Aug 28.

DOI:10.1016/j.ejso.2022.08.023
PMID:36064631
Abstract

OBJECTIVE

To understand the tumor burden of peritoneal metastases (PM) in China, and to guide the construction of professional PM treatment centers in China.

METHODS

Based on the cancer statistics by the National Cancer Center of China published in 2016, the prevalence of PM in 2020 was calculated according to the population statistics in China and the survival and mortality rates of various PM.

RESULTS

The prevalence rates of PM in China were as follows: gastric cancer PM 371.0/million, absolute number 523,937; colorectal cancer PM 47.1/million, absolute number 66,482; ovarian cancer PM 97.1/million, absolute number 137,083; pseudomyxoma peritonei 25.1/million, absolute number 35,425; malignant peritoneal mesothelioma 2.6/million, absolute number 3737; the above total was 766,664. According to the annual high-quality treatment volume of 365 cases in each professional PM treatment center, China needs to establish 1194 specialized PM treatment centers. At present, there are 1580 tertiary first-class hospitals in China. Therefore, for every 3 first-class tertiary hospitals in China there should be at least 2 PM treatment centers in full operation.

CONCLUSIONS

Considering the large number of PM patients in China and the relatively small number of professional PM treatment centers, more resources should be devoted to the promotion and construction of PM treatment centers.

摘要

目的

了解中国腹膜转移瘤(PM)的肿瘤负担,并指导中国专业PM治疗中心的建设。

方法

根据中国国家癌症中心2016年发布的癌症统计数据,依据中国人口统计数据以及各类PM的生存率和死亡率,计算2020年PM的患病率。

结果

中国PM的患病率如下:胃癌PM为371.0/百万,绝对数为523,937;结直肠癌PM为47.1/百万,绝对数为66,482;卵巢癌PM为97.1/百万,绝对数为137,083;腹膜假黏液瘤为25.1/百万,绝对数为35,425;恶性腹膜间皮瘤为2.6/百万,绝对数为3737;以上总计766,664。按照每个专业PM治疗中心每年365例的高质量治疗量计算,中国需要建立1194个专门的PM治疗中心。目前中国有1580家三级甲等医院。因此,在中国每3家三级甲等医院至少应有2家全面运营的PM治疗中心。

结论

鉴于中国PM患者数量众多而专业PM治疗中心数量相对较少,应投入更多资源用于PM治疗中心的推广和建设。

相似文献

1
Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate.中国腹膜转移瘤的临床流行病学:基于患病率构建专业腹膜转移瘤治疗中心
Eur J Surg Oncol. 2023 Jan;49(1):173-178. doi: 10.1016/j.ejso.2022.08.023. Epub 2022 Aug 28.
2
Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastases from colorectal cancer in the Czech Republic in 2018.2018 年捷克共和国结直肠癌细胞减灭术联合腹腔热灌注化疗治疗腹膜转移癌的临床分析
Klin Onkol. 2021 Summer;34(4):278-282. doi: 10.48095/ccko2021278.
3
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.结直肠和阑尾腹膜转移的细胞减灭术和腹腔热灌注化疗(HIPEC)-香港经验和文献复习。
Asian J Surg. 2021 Jan;44(1):221-228. doi: 10.1016/j.asjsur.2020.05.010. Epub 2020 Jun 27.
4
[Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].[细胞减灭术及腹腔内热灌注化疗(HAPP)治疗腹膜癌病]
Minerva Chir. 2002 Oct;57(5):597-605.
5
Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy.腹膜恶性肿瘤与腹腔热灌注化疗
Surg Clin North Am. 2020 Jun;100(3):589-613. doi: 10.1016/j.suc.2020.02.009. Epub 2020 Apr 16.
6
Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases.组织学亚型和全身转移对同时性结直肠腹膜转移患者的治疗及生存有强烈影响。
Eur J Surg Oncol. 2016 Jun;42(6):794-800. doi: 10.1016/j.ejso.2016.03.014. Epub 2016 Mar 28.
7
[The status analysis of diagnosis and treatment of synchronous peritoneal carcinomatosis from colorectal cancer in China: a report of 1 003 cases in 16 domestic medical centers].中国结直肠癌同期腹膜转移癌的诊治现状分析:国内16家医疗中心1003例报告
Zhonghua Wai Ke Za Zhi. 2019 Sep 1;57(9):666-672. doi: 10.3760/cma.j.issn.0529-5815.2019.09.005.
8
Peritoneal metastases found in routinely resected specimens after cytoreductive surgery and heated intraperitoneal chemotherapy.在细胞减灭术后和腹腔内热化疗后常规切除标本中发现腹膜转移。
Eur J Surg Oncol. 2022 Apr;48(4):795-802. doi: 10.1016/j.ejso.2021.12.026. Epub 2021 Dec 25.
9
Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.结直肠腹膜转移的细胞减灭术和腹腔热灌注化疗的演变:8 年单中心经验。
Dis Colon Rectum. 2019 Oct;62(10):1195-1203. doi: 10.1097/DCR.0000000000001456.
10
Management of colorectal cancer patients at high risk of peritoneal metastases.腹膜转移高危结直肠癌患者的管理
J BUON. 2015 May;20 Suppl 1:S71-9.

引用本文的文献

1
Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.亚洲关于胃癌腹膜转移常温腹腔及全身治疗的共识
Gastric Cancer. 2025 Jul 14. doi: 10.1007/s10120-025-01631-9.
2
Clinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases.肿瘤浸润淋巴细胞在恶性腹膜间皮瘤中的临床意义:一项143例单中心研究
Ann Surg Oncol. 2025 May 15. doi: 10.1245/s10434-025-17437-z.
3
A novel nebulized drug delivery system based on an innovative high-pressure peristaltic pump availably applied to pressurized intraperitoneal aerosol chemotherapy.
一种基于创新型高压蠕动泵的新型雾化药物输送系统,可有效应用于加压腹腔雾化化疗。
J Gastrointest Oncol. 2025 Feb 28;16(1):234-248. doi: 10.21037/jgo-2024-1009. Epub 2025 Feb 23.
4
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy.恶性腹膜间皮瘤的潜在治疗方法:自然杀伤细胞免疫疗法的体内和体外实验研究
Cancer Biol Med. 2024 Nov 1;21(11):1078-94. doi: 10.20892/j.issn.2095-3941.2024.0218.
5
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.腹膜假性黏液瘤患者免疫微环境及免疫相关治疗的研究进展。
Cancer Biol Med. 2024 Jul 18;21(7):586-605. doi: 10.20892/j.issn.2095-3941.2024.0109.
6
Postoperative Bloodstream Infections in Patients with Peritoneal Surface Malignancies Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Risk Factors and Pathogen Resistance.接受细胞减灭术和腹腔内热灌注化疗的腹膜表面恶性肿瘤患者术后血流感染:危险因素与病原体耐药性
Infect Drug Resist. 2024 Jun 17;17:2405-2415. doi: 10.2147/IDR.S462639. eCollection 2024.
7
A nomogram prediction model of pseudomyxoma peritonei established based on new prognostic factors of HE stained pathological images analysis.基于 HE 染色病理图像分析的新预后因素建立的腹膜假性黏液瘤预测模型。
Cancer Med. 2024 Mar;13(6):e7101. doi: 10.1002/cam4.7101.
8
Long-term survival in patients with PMP: a single-institutional retrospective study from China.中国单机构回顾性研究:PMP 患者的长期生存。
World J Surg Oncol. 2023 Oct 28;21(1):347. doi: 10.1186/s12957-023-03232-1.
9
Etiological analysis of infection after CRS + HIPEC in patients with PMP.PMP 患者行 CRS + HIPEC 术后感染的病因分析。
BMC Cancer. 2023 Sep 26;23(1):903. doi: 10.1186/s12885-023-11404-1.
10
Molecular Histopathology for Establishing Diagnostic Method and Clinical Therapy for Ovarian Carcinoma.用于建立卵巢癌诊断方法和临床治疗的分子组织病理学
J Clin Med Res. 2023 Feb;15(2):68-75. doi: 10.14740/jocmr4853. Epub 2023 Feb 28.